Introduction
Pulmonary sporotrichosis is a rare infection caused by the dimorphic fungus Sporothrix schenckii and even more rarely by other Sporothrix spp. In recent decades, there has reviews [5, 6] confi rmed such discrete patterns and suggested likely differences in response to therapy. However, choosing an appropriate treatment remains diffi cult and information on the role of newer azole antifungal agents is lacking.
We report two cases of primary pulmonary sporotrichosis with cavitary disease presenting as management challenges and review all case reports in the English literature with regard to the clinico-radiological patterns of presentation and response to treatment. Our hypotheses were: (i) the clinico-radiological presentation patterns of pulmonary involvement differ between primary pulmonary and multifocal sporotrichosis, and (ii) treatment outcomes differ in respect to the different clinico-radiological patterns of presentation.
Case reports

Case 1
A 64-year-old man with a history of primary pulmonary sporotrichosis presented with productive cough, fever and signifi cant hemoptysis in the setting of an infl uenza-like illness. He was a keen rose gardener, a heavy smoker with known emphysema and rheumatoid arthritis, and on longterm prednisolone, methotrexate and adalimumab. His sporotrichosis was diagnosed four years earlier following a similar presentation. Chest X-rays and computed tomography (CT) at that time showed bilateral upper lobe cavitary lesions. His diagnosis was confi rmed by bronchoscopy washings and sputum cultures which were positive for S. schenckii . Treatment with itraconazole, 200 mg twice daily, was employed for a year but his disease progressed radiologically over the ensuing years. Cardiothoracic opinion was sought at an early stage but surgery was not pursued. Approximately one year prior to admission, he had a relapse of chronic productive cough. Repeat cultures of sputum specimens yielded S. schenckii . Antifungal susceptibility tests were organized at the South Australian mycology reference laboratory which indicated minimum inhibitory concentrations (MICs) for amphotericin B of 2.0 mg/l (intermediate susceptibility), itraconazole of 0.5 mg/l (dose-dependent susceptibility), voriconazole at 1.0 mg/l (susceptible), and posconazole of 1.0 mg/l (resistant). These interpretations of the data are in accordance with Clinical and Laboratory Science Institute (CLSI) breakpoints. He was again started on voriconazole, 200 mg twice daily, which he had been taking till admission.
On admission, the patient was cachectic with poor air entry in both upper lung fi elds. Repeat CT chest showed further progression of bilateral thick-walled apical cavities with the left cavity containing debris (Fig. 1A) . Empiric antibiotic treatment was commenced for presumed bacterial super-infection. Initial serology was strongly positive for infl uenza A and sputum yielded Staphylococcus aureus in culture.
Five days post-admission, the patient suddenly developed a massive hemoptysis requiring emergency intubation and mechanical ventilation. Urgent CT angiogram confi rmed hemorrhage from a left upper lobe pulmonary vein that eroded into the cavity wall (Fig. 1B ). An emergency left upper lobectomy was performed and subsequent cultures from the resected lung tissue yielded S. schenckii , S. aureus and Achromobacter spp. Initial sputum cultures also led to the recovery of S. schenckii ( Figure 1C -E) . The patient received a further two weeks of antibiotics postsurgery, recovered well and was discharged home on longterm voriconazole therapy. Six months later, he had ongoing respiratory symptoms and gradual weight loss from residual cavitary lesion in the right upper lobe, although his sputum cultures remained negative for S. schenckii .
Case 2
A 60-year-old man with severe emphysema (FEV1/FVC of 27.4%) presented in respiratory failure with three days of productive cough. He had a 40 pack/year smoking history and recent hospitalization for myocardial infarction. Chest X-ray ( Fig. 2A ) on admission showed left apical pleural scarring with a large, thick walled cavity in the upper lobe. High-resolution chest CT (Fig. 2B ) confi rmed bullous emphysema and infl ammatory changes in the cavity. A course of intravenous antibiotics, bronchodilators and steroids initially improved his clinical situation. Multiple cultures sputum culturers subsequently yielded S. schenckii and the patient was started on long-term itraconazole, 200 mg twice daily. Reviewing the results from his sputum cultures of his earlier admission for myocardial infarction revealed that S. schenckii was also present at that time. The patient was not fi t for surgery and was treated conservatively. Six months later his symptoms remained stable and he has continued on itraconazole. A year later, he was readmitted with superimposed bacterial infection and subsequently died from complications of respiratory failure before amphotericin treatment could be initiated.
Methods
A literature search of all published cases in the English language within the last 50 years (1960 -2010) was conducted using online databases (PubMed, EMBASE and Medline). Key search terms included ' pulmonary sporotrichosis ' , ' Sporothrix infection of lungs ' and ' Sporothrix clinical and radiological details. Clinical information from case reports was analyzed with regards to patient characteristics, risk factors, clinico-radiological presentation, treatment modalities and outcomes.
schenckii pulmonary infections ' . Articles were also obtained through hand-searches. Case reports were included if they described any form of pulmonary involvement of Sporothrix infections but were excluded if they lacked Defi nitions ' Medical treatment ' was defi ned as treatment either alone, in combination or sequentially with one or more classes of antifungal medication. ' Primary surgery ' was defi ned as surgical removal of the affected portions of the lung without prior initiation of medical treatment. This included patients in whom surgery was performed to obtain diagnoses and subsequently confi rmed as Sporothrix infections. Patients who received less than seven days of medical treatment before surgery were also considered as having ' primary surgery ' . ' Rescue surgery ' was defi ned as surgical treatment due to perceived failure of medical therapy. Patients who had multiple surgical procedures for sporotrichosis were also considered as having ' rescue surgery ' . Outcome was defi ned as ' success ' if there was an improvement in clinical symptoms, as well as negative sputum cultures for Sporothrix after initiation of treatment. Patients whose outcome was reported ' well ' without further details were considered as having successful outcome. Outcome was defi ned as ' contained ' if there were ongoing clinical symptoms and/or positive sputum cultures despite treatment.
Statistical analysis
Categorical variables were expressed as counts and proportions whereas continuous numerical variables were expressed as mean Ϯ standard deviation. Comparisons of categorical variables between the primary pulmonary and multifocal sporotrichosis groups were performed with Pearson ' s Chi-square analysis with Yate ' s correction (GraphPad Prism 4.0; GraphPad Software, San Diego, CA, USA). The same methods were used to compare treatment outcomes between the cavitary and noncavitary groups, and within the cavitary primary pulmonary sporotrichosis group. Unpaired t -tests were used to compare the age of patients. For both t -tests and Chisquare tests, a two-sided P -value of Ͻ 0.05 was considered statistically signifi cant.
Results
A total of 90 reports were identifi ed and 86 cases were included in the fi nal analysis which included 64 (74.4%) cases of primary pulmonary sporotrichosis and 22 (25.6%) cases of multifocal disease [4,6 -65] . Four cases were excluded due to: (i) lack of clinico-radiological details (one case) [66] , (ii) duplicate publications (two cases) [67, 68] and (iii) inability to obtain the report (one case) [69] . Of the cases included, 51 were previously described by Pluss [4,6 -13,15 -28,31,32,35,37 -44,67,69] . Eighty-three (96.5%) of reported cases were caused by S. schenckii , with one case each due to (1.2%) S. schenckii var. luriei , S. gougerotii and S. cyanescens . Seventy-six (88.4%) cases were from the USA, three (3.5%) from South Africa, two (2.3%) from Brazil and one (1.2%) each from Canada, Democratic Republic of Congo, India, Italy and Sudan. Clinical details of non-S. schenckii cases are provided in Table 1 but they were analyzed together with S. schenckii cases to include all cases of pulmonary sporotrichosis.
The mean age of patients on fi rst presentation with clinical symptoms was 47.7 Ϯ 12.3 years for primary pulmonary sporotrichosis and 48.4 Ϯ 12.1 years for those with multifocal infections ( P ϭ 0.82). Overall, there were no differences between the two groups in terms of sex ratios and underlying respiratory conditions (Table 2) . There was more immunosuppressant use in patients with multifocal sporotrichosis (36.4% vs. 3.1%, P ϭ 0.0001) but no other signifi cant differences in risk factors were apparent. Possible or confi rmed exposure to occupational and environmental sources of infection was similar within the two groups. Such exposures were defi ned as any reported occupational or recreational contacts with plant materials (sphagnum moss, fl owers, roses, vegetables and blackberries), animals (meatpacking, contacts with horses and deers) and soil particles (brickmason and gardening activities).
Nine (14.1%) patients with primary pulmonary sporotrichosis were asymptomatic and diagnosed incidentally. There were no signifi cant differences in symptoms between the two groups except for hemoptysis, which was more common in primary pulmonary disease (42.2% vs. 9.1%, P ϭ 0.01). Extra-pulmonary involvement in multifocal sporotrichosis included skin only (seven cases, 31.8%), skin and joints (six cases, 27.3%), skin and bone (two cases, 9.1%), and one (4.5%) case each of joint only, upper airways only, skin and brain, skin and perianal region, skin, joint and upper airways, skin joint and bones, and widespread multiorgan dissemination. Skin involvement (18 cases, 81.8%) was the most common extra-pulmonary manifestation in multifocal sporotrichosis followed by joint involvement (10 cases, 45.4%). The differences in radiological patterns observed between primary pulmonary and multifocal sporotrichosis are summarized in Table 3 . Overall, 51 (59.3%) cases had cavitary disease while in 35 (40.7%) cases there were no cavitary presentations. Cavitary manifestations were more common in primary pulmonary sporotrichosis while noncavitary patterns were more common in multifocal disease ( P ϭ 0.0001). Two patients who displayed cavitary lesions in multifocal sporotrichosis group had initial clinical features consistent with primary pulmonary sporotrichosis, but they were classifi ed within the multifocal group due to extra-pulmonary manifestations later in the course of the disease. Most patients with primary cavitary disease presented with upper lobe involvement as opposed to diffuse infi ltrates which were commonly seen in patients with multifocal disease.
The key diagnostic investigations for the diagnosis of primary pulmonary and multifocal sporotrichosis are summarized in Table 4 . Culture inoculated with sputum and bronchoscopic specimens were the mainstay in the diagnosis in primary cavitary pulmonary sporotrichosis whereas tissue samples of skin and joints established the diagnosis in the majority of cases of multifocal sporotrichosis.
Clinical outcomes of various treatment modalities in different clinico-radiological forms of pulmonary sporotrichosis are summarized in Table 5 treatment for pulmonary sporotrichosis, spontaneous resolution occurred in two (22.2%), none had contained disease, death from disease occurred in two (22.2%), unrelated death in four (44.4%) and unknown outcome was noted in one (11.1%). Of all the 86 cases, 72 (83.7%) patients received some form of medical therapy, either alone or in combination with surgery. The details of antimicrobial treatment given are provided in Table 5 . Twelve (16.7%) had amphotericin B and azole treatment (in combination or in succession), while 34 (47.2%) had amphotericin B only without azoles, and a further 10 (13.9%) had only azole therapy without amphotericin B. A total of 16 (22.2%) did not receive amphotericin B/non-azole regimens, in opposition to the current guidelines. Overall success rates reported were fi ve patients of 12 (41.7%) who received amphotericin B and azole (in combination or succession), 15 of 34 (44.1%) treated with only amphotericin B, and fi ve of 10 (50.0%) with azole only treatment. Surprisingly, 13 of 16 (81.3%) of cases who were treated with neither amphotericin nor azole had successful outcomes.
Overall, only 12 (16.7%) patients received itraconazole therapy (six primary pulmonary and six multifocal sporotrichosis) which is in keeping with the current guidelines. Of these individuals, eight (66.7%) had successful outcomes, two (16.7%) died and for two (16.7%) the outcomes were unknown. Among the six primary pulmonary sporotrichosis patients treated with itraconazole, the therapy was successful for three (50.0%), one (16.7%) died and for two (33.3%) the outcomes were unknown. In contrast the six patients with multifocal sporotrichosis who received itraconazole, the disease resolved for fi ve (83.3%) and one (16.7%) died.
A total of 19 deaths (22.5%) were reported, of which 14 were directly due to complications of the underlying Sporothrix infection. The fi ve remaining patients whose deaths were deemed unrelated to sporotrichosis did not receive any form of therapy.
Discussion
Our analysis represents the only review to date using pooled data from individual case reports. We found signifi cant differences in outcomes based on clinicoradiological patterns and these results provide a potential paradigm shift in disease management. In general terms, treatment options for pulmonary sporotrichosis are either (i) medical treatment alone or (ii) surgical intervention with or without adjuvant medical therapy. The mainstay of medical treatment has gradually shifted towards azole-based regimens. Current treatment guidelines [1, 3] recommend longterm itraconazole as fi rst line agent, while amphotericin B is reserved for life-threatening situations. Surgical intervention is only recommended for localized infections or those in which medical therapy has failed, while saturated solution of potassium iodide (SSKI) treatment is no longer a preferred therapy. Based on these guidelines, all patients presenting with non-life threatening pulmonary sporotrichosis would be treated with itraconazole regardless of the disease pattern. However, our analysis highlighted that optimal management of pulmonary sporotrichosis should be based much more on clinico-radiological manifestations.
In keeping with previous fi ndings [4, 5, 70, 71] , the majority of patients with primary pulmonary sporotrichosis displayed cavitary pattern on radiology, whereas those with multifocal infections predominantly had bibasal or diffuse reticulonodular infi ltrates. This is not surprising as primary pulmonary sporotrichosis is thought to be due to direct inhalation of conidia from the environment with subsequent inoculation in structurally abnormal lungs [5, 6, 70] . This triggers chronic suppurative and/or granulomatous infl ammatory responses over time [71] with subsequent breakdown of necrotic lung tissue and cavity formation. Inhalation route may also account for frequent involvement of upper lobes while gradual low-grade immune responses may account for patients remaining asymptomatic until large cavitations develop. In multifocal sporotrichosis, pulmonary seeding from a distant focus via hematogenous or lymphatic routes [64] , would lead to a predominantly diffuse or bibasal reticulonodular infi ltrate pattern. The role of hypersensitivity response to fungal antigens has also been implicated in producing pleural effusions associated with sporotrichosis [42] . Amongst the cases reviewed, there were a few exceptions to the radiographic patterns. Fifteen cases of primary pulmonary sporotrichosis did not have cavitary patterns while two patients with multifocal sporotrichosis had cavitations. The underlying reasons for this were not clear but nine of the 15 patients with primary pulmonary sporotrichosis had changes confi ned to a single lobe of the lung, possibly representing an early nodular or infi ltrative disease before the development of cavitations. It may also represent different patterns of host responses to the infection. In contrast, one multifocal sporotrichosis case [41] probably had two concurrent primary sites of infection (skin and lung), whereas the other [22] with perianal disease became apparent after the diagnosis of primary respiratory infection.
By analyzing the treatment outcomes of primary pulmonary sporotrichosis according to cavitary or noncavitary patterns of presentation, it was obvious that once cavitary disease developed, medical treatment alone failed to eradicate the infection. This was evident in both of our cases where they continued to have symptoms and positive sputum cultures despite the long duration of treatment. The likely explanations for this are: (i) variable bioavailability and plasma concentrations of oral antifungal agents, particularly itraconazole [72], (ii) inadequate penetration of antifungal agents into the cavity, and (iii) surrounding areas of fi brosis in advanced disease further limiting drug delivery [73] . In contrast, medical treatment alone is entirely appropriate in multifocal sporotrichosis, as well as early primary pulmonary infections, as drug delivery to non-cavitating tissues is likely to be better. Although we found favorable response rates to medical therapy in multifocal sporotrichosis patients, treatment failure and death rates were also high, probably due to the immunosuppressed state of many of these individuals.
Theoretically, primary surgery should be more beneficial than rescue surgery as a delay in surgery may lead to the development of more advanced disease, larger cavity size, formation of complex cavities or spill-over lesions in adjacent lobes, thereby increasing the chances of surgical failure and residual infective foci. Moreover, the patient ' s general health may further deteriorate, or lead to lifethreatening hemoptysis, as seen in Case 1, thus making successful surgery diffi cult. However, no statistically signifi cant differences in outcomes were detected between primary and rescue surgery for cavitary primary pulmonary sporotrichosis in this study. In addition, the role of adjuvant medical treatment in the peri-operative period to reduce the burden of disease pre-surgery and/or eradicate any residual disease post-surgery [40] remains unclear. The role of intra-cavitary antifungal therapy has also not been explored thus far.
From the standpoint of overall effi cacy of medical treatment, it is surprising to fi nd that non-amphotericin and non-azole based regimens offered the best chance of success. This information has to be interpreted with caution, as these cases of pulmonary sporotrichosis may represent milder and uncomplicated forms where the host immunity alone was suffi cient to eradicate the infection without any real effect from the treatment. On the other hand, modest success rates of any amphotericin and/or azole therapy may represent the cases with signifi cant disease burden and complications where the outcome of treatment may remain poor regardless of therapy. Although the effi cacy of triazole agents in the treatment of cutaneous and articular sporotrichosis is well-established, current experience with itraconazole in the treatment of pulmonary sporotrichosis is still very limited, with only 12 cases identifi ed to date. There has been no convincing data on successful treatment outcomes with itraconazole, particularly for cavitary primary pulmonary sporotrichosis, although the outcomes appear to be much better for non-cavitary disease.
Finally, our cases represented the fi rst reports of primary pulmonary sporotrichosis from Australia. In addition, an interesting aspect of Case 1 was that S. schenckii isolate displayed susceptibility to voriconazole in vitro . This is in contrast to the published data where the MIC range was reported as 4 -16 mg/l and thus S. schenckii isolates were considered innately resistant to voriconazole [74] . Although cutaneous sporotrichosis cases are common throughout Australia [75 -77] , there has been no published data to date regarding the voriconazole susceptibilities for any clinical isolates of S. schenckii from this region. It remains possible that geographical variations in antimicrobial susceptibilities do indeed exist for Sporothrix . Hence, further in vitro susceptibility data for local isolates are much needed. Nevertheless, our fi rst case represented clinical failure, initially to itraconazole, and subsequently to voriconazole despite the agent being found in vitro to be susceptible, therefore adding further to the argument that early surgery should have been considered.
An inherent limitation of reviewing rare conditions such as pulmonary sporotrichosis is the lack of randomized control trials. Collective experience gleaned from case reports can be helpful but there are invariable limitations. Although we have analyzed a large cohort of reported cases, some lacked detailed clinical information; others did not clarify specifi c treatment end points and duration of follow-up also varied ranging from none to a few weeks to years; and in some cases that responded to treatment, the fi nal outcome was limited by the timing of reporting. In the absence of implicitly described clinical and microbiological details on outcomes in some cases, misclassifi cation of treatment outcomes were inevitable although this bias would likely be non-differential between the treatment groups with tendency to overestimate successful outcomes.
Conclusions
Pulmonary sporotrichosis presents as two forms: (1) primary pulmonary infection which often displays cavitary pattern, and (2) as part of multifocal infection which presents as non-cavitary disease. Treatment options should be directed according to these clinico-radiological patterns of presentation. In the absence of cavitation, medical treatment alone would seem reasonable. However, once cavitations develop, surgical management should be considered early in the course of the disease, even for bilateral presentation, provided that the patient has adequate predicted respiratory reserves post-surgery, as late surgery may result in poorer outcomes and complications. Current experience in treating cavitary disease with itraconazole alone is limited.
